Drug Development Pipeline
Vancomycin Inhalation Powder (AeroVanc™)
Vancomycin inhalation powder (AeroVanc™) is an inhaled dry powder version of the antibiotic vancomycin for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) airway infection in people with CF.
A phase 3 study of AeroVanc™ in people with CF who have Methicillin-resistant Staphylococcus aureus (MRSA) lung infection did not meet its primary endpoint of change in FEV1 (lung function). Additionally, treatment with AeroVanc did not result in a reduction in pulmonary exacerbations compared to placebo. No further development in CF is planned at this time.
This program is sponsored by Savara Pharmaceuticals and partially funded by the Cystic Fibrosis Foundation. It was conducted within the Therapeutics Development Network.
Recent Vancomycin Inhalation Powder (AeroVanc™) Studies
Completed with Results
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More